Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?

The identification of certain genomic alterations (EGFR, ALK, ROS1, BRAF) or immunological markers (PD-L1) in tissues or cells has led to targeted treatment for patients presenting with late stage or metastatic lung cancer. These biomarkers can be detected by immunohistochemistry (IHC) and/or by mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofman, Véronique, Lassalle, Sandra, Bence, Coraline, Long-Mira, Elodie, Nahon-Estève, Sacha, Heeke, Simon, Lespinet-Fabre, Virginie, Butori, Catherine, Ilié, Marius, Hofman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876645/
https://www.ncbi.nlm.nih.gov/pubmed/29534030
http://dx.doi.org/10.3390/cancers10030070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876645/
https://www.ncbi.nlm.nih.gov/pubmed/29534030
http://dx.doi.org/10.3390/cancers10030070

Ejemplares similares